Introduction The U.S. Food and Drug Administration has approved the first FDA gene therapy for inherited deafness, a one-time treatment that restored measurable hearing in 80% of evaluable pediatric patients during clinical testing. The therapy, marketed as Otarmeni (lunsotogene parvec-cwha), targets a specific genetic cause of profound hearing loss tied to mutations in the OTOF...
